諾華製藥 NVS 深 滬
等待開盤 08-10 09:30:00 美东时间
156.33
+2.120
+1.37%
華盛通- 最 高156.6802
- 今 開156.56
- 成交量 130.91万股
- 最 低 155.38
- 昨 收 154.21
- 總市值 2.97亿
- 52周最高 167.3788
- 市盈率 靜 21.74
- 換手率 0.01%
- 52周最低 118.4888
- 委 比 98.82%
- 總股本 0.02亿
- 歷史最高 167.3788
- 量 比 0.92
- 振 幅 0.84%
- 歷史最低 3.8803
- 每 手 1
- 風險率 13.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Novartis gains UK approval of Rhapsido for urticaria
The UK's Medicines and Healthcare products Regulatory Agency has approved Novartis' (NVS) Rhapsido (remibrutinib) for chronic spontaneous urticaria. The approval of the BTK inhibitor was based on the ...
08-07 01:25
集采“上新”：反内卷新规生效，临床选择丰富
此次集采没有出现太多极端报价，除了个别竞争较大的产品，总体来说价格竞争比以往温和了一些。 第12批国家药品集中带量采购于7月31日正式开标。65个品种全部采购...
08-01 19:24
Novartis gains expanded indication for Pluvicto
The US FDA has approved an expanded indication for Novartis' (NVS) Pluvicto (lutetium Lu 177 vipivotide tetraxetan) so that it can be used across all stages of PSMA-positive metastatic prostate cancer...
08-01 05:26
诺华制药（NVS）Q2核心新药增势显著 老药受仿制药冲击下滑
经济观察网 诺华制药（NVS）2026年第二季度业绩分化，五大新药销售额同比大增，三款老药受仿制药冲击下滑明显。 业绩经营情况： 五大新药（Kisqali、K...
08-01 04:44
Monte Rosa, BioAge plunge as Novo’s setback casts a shadow over pipeline
Shares of Monte Rosa Therapeutics (GLUE) and BioAge Labs (BIOA) fell sharply on Friday after a late-stage trial setback for Novo Nordisk (NVO) called into question the mechanisms underlying their expe...
08-01 02:09
Immutep Quarterly Activities Report Q4 FY26
Immutep Limited provided an update on its activities for Q4 FY26, highlighting progress in its eftilagimod alfa (efti) program and IMP761 development. Pooled analysis of five efti trials showed a 7.7-month median overall survival benefit in biological responders across four tumor types. IMP761, the only LAG-3 agonist antibody in clinical development, met its primary safety endpoint and demonstrated significant pharmacodynamic activity in a first-...
07-30 12:00
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
Dr. Debra Jeske Zack, a seasoned immunologist with over 25 years of experience, has been appointed as Spero Therapeutics' Chief Medical Officer. Her expertise will strengthen the company's clinical leadership as it advances SP001, a Phase 2-ready third-generation anti-CD40L antibody targeting IgG4-related disease and other immune-mediated conditions. Dr. Zack's leadership is expected to accelerate the development of innovative therapies for patie...
07-27 12:00
J&J, Gilead among recipients of EU drug recommendations this week
An expert panel of the EU drug regulator, the European Medicines Agency, endorsed 12 new medicines and eight label expansions for approval this week, including products from U.S. drugmakers such as Jo...
07-24 22:54
Pharmaceuticals still a defensive play amid AI and geopolitical anxieties – analyst
Rajesh Kumar, head of European Life Sciences & Healthcare Equity Research at HSBC, positioned healthcare (XLV) as a defensive haven amid growing investor anxiety about AI investments and geopolitical ...
07-22 00:02
